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Circulating and ex vivo production of interleukin (IL)-l/3, tumor necrosis factor (TNF)-a, IL-6, 
and IL-1 receptor antagonist (ra) and the diagnostic utility of these cytokines were studied in 
123 patients with fever of unknown origin (FUO). Diagnoses were infections, 28; neoplasms, 14; 
noninfectious inflammatory diseases (NI1D), 32; miscellaneous diseases, 10; and none made, 39. IL- 
1/3, IL-6, and IL-lra concentrations were higher in patients with infections, neoplasms, and NIID 
than in healthy controls, Patients with infections had higher concentrations of TNF-a than controls. 
The ex vivo production of IL-1 P and IL-lra in all patients with FUO did not differ from that in 
controls; however, production of TNF-a was lower in patients with neoplasms and NIID, and IL-
6 production was lower in patients with neoplasms. Thirty-five patients with fever did not have 
elevated cytokines. Although some significant differences were found among the diagnostic sub­
groups, there was wide variation. Thus, measurement of these cytokines does not aid in the diagnosis 
of FUO.
Fever o f  unknown origin (FUO; >38.3°C  for > 3  weeks and 
no diagnosis after 1 week o f  in-hospital evaluation [1]) is a 
challenging clinical problem. The bona fide endogenous pyro­
gens are the pro inflammatory cytokines interleukin (IL)-l/?, 
tumor necrosis factor (TN F)-a, IL-6, and interferon-a [2]. 
These are involved in various immunologic and inflammatory 
processes and act directly on the temperature regulation center 
in the hypothalamus [2]. I f  the elevated temperature in patients 
with FUO represents genuine fever, the set point at the tempera­
ture center in the preoptic area of the hypothalamus is elevated, 
which, according to the prevailing concept, is mediated by 
endogenous pyrogens entering the hypothalamus via the blood­
stream. Thus, one or more endogenous pyrogens should be 
present in the circulation in these patients, and measurement 
o f these cytokines could lead to insight in the pathogenesis o f  
fever. In a prospective cohort o f  patients with FUO, we exam­
ined this pathophysiologic concept by measuring 1L-1/3, TNF-
a ,  and IL-6 in the circulation. We also measured the concentra-
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tions o f circulating antiinflammatory cytokine IL-1 receptor 
antagonist (ra), which is thought to be under the same control 
as IL -1/3 [3]. In addition, we addressed the question o f  whether 
determination o f  these circulating cytokines or cytokine pro­
duction capacity o f  blood cells is useful in the diagnostic pro­
cess o f FUO.
Materials and Methods
i
Patients. All 167 patients fulfilling the criteria for FUO were 
studied prospectively from January 1992 until January 1994 in 
all eight Dutch university hospitals. Blood samples for cytokine 
measurements were drawn from 123 patients, none of whom used 
cyclooxygenase inhibitors or corticosteroids.
Blood samples. Blood was drawn from the antecubital vein 
and collected into three 4-mL endotoxin-free EDTA tubes. Body 
temperature and time of venipuncture were noted. Most blood 
was collected between 10 a .m . and 2 P.M. by one investigator 
(E.M.H.A.d.K.) and processed as described elsewhere [4].
Cytokine measurements. IL-1/3, TNF-a, and IL-lra were mea­
sured by RIA as described [4]. Interassay variation of the RIAs is 
<15% , and intraassay variation is <10%. The sensitivity of the 
assay with a 100-^L sample was 20 pg/mL for IL-lra, IL-1/3, and 
TNF-a:. The TNF-a assay measures both free and soluble receptor- 
bound TNF-a. IL-6 was measured by ELISA (CLB, Amsterdam) 
according to the manufacturer’s directions [5]. The lower limit o f  
detection o f the ELISA is 3 pg/inL. There is no interference o f  
soluble (s) IL-6R, All samples from the same patient were analyzed 
in duplicate. Control values were determined from 20 healthy sed­
entary volunteers for IL-1/3, IL-lra, and TNF-a and from 50 
healthy controls for IL-6, Median values (range) for circulating 
cytokines were as follows: IL-1/?, 40 pg/mL (20-65); TNF-a, 
92.5 pg/mL (65-120); IL-6, <3 pg/mL; and IL-lra, 212.5 pg/mL 
(110-490). Medians (range) for cytokine ex vivo production were
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IL-1/3, 6.5 ng/mL (2.2-15.5): TNF-a, 6.8 ng/mL (1.8-9.7); IL-
6, 17.7 ng/mL (4.8-33.5), and IL-lra, 10.8 ng/mL (7.2-16.8).
,Statistical analysis. The Kruskal-Wallis nonparametric, 
Dunn’s multiple comparison, and Mann-Whitney tests were used 
for statistical comparison of the median values of groups of patients 
with different diagnoses and of controls. Spearman’s rank test was 
used to assess correlations because of non-Gaussian distribution. 
Multivariate analysis (multiple regression) was used to evaluate 
the effect on cytokine levels with the following variables: diagnosis 
category, sex, age, time of venipuncture (before or after 1 p.m.), 
fever pattern (continuous or recurrent), number of days between 
start of fever and venipuncture, fever course after venipuncture 
(descending, increasing, or stable), body temperature at venipunc­
ture, and hospital in which blood was obtained. We could not 
include normal values in the multiple regression analysis.
Results
Patient characteristics. The median age for the 123 pa­
tients was 52 years (range, 16-87). There were 61 males and 
62 females. Seven patients died of the underlying disease caus­
ing the fever.
Circulating cytokines (figure 1). Median circulating 1L-1/3 
concentrations for all patients was 55 pg/mL (range, 20-150), 
Median IL-1/3 concentrations for all 5 diagnostic groups and 
controls differed (P < .005). Patients with neoplasms, infec­
tions, and noninfectious inflammatory diseases (NIID) had sig­
nificantly higher median circulating IL-1/3 than control subjects 
IP <  .05), but there were no significant differences between 
diagnostic groups.
Median circulating TNF-a concentrations for all patients 
with FUO was 110 pg/mL (range, 20-510). Patients with infec­
tions had significantly higher median circulating TNF-a than 
controls (P <  .01). There were no differences between diagnos­
tic groups.
Median circulating IL-6 concentration for all patients was 
not determined (range, 0-2190 pg/mL). Patients with malig­
nancies, infections, and NIID had higher levels of IL-6 than 
normal controls (P <  .001). Patients with malignancies had 
higher levels than those with no diagnosis or miscellaneous 
disorders (P <  .05).
Median circulating IL-lra concentration in all patients with 
FUO was 320 pg/mL (range, 0-2100). Patients with neo­
plasms, infections, and NIID had significantly higher median 
circulating IL-lra than controls (P < .01). Patients with neo­
plasms had higher levels of IL-lra than those with NIID (P < 
.01). By multiple regression analysis, some explanatory vari­
ance was found. Higher IL-lra levels were associated with 
increasing age, presence of continuous fever, and lower body 
temperature. Multiple regression analysis also indicated that 
patients with infections and malignancy had higher levels of 
IL-lra than patients with no diagnosis.
Ex vivo cytokine production (figure 2). The median ex vivo 
production of IL-1/3 for all patients with FUO was 8.4 ng/mL 
(range, 0-47.9). There were no significant differences between
the subgroups and normal subjects. By multiple regiession 
analysis, some explanatory variance was found: Oldei patients 
tended to produce more IL-1/3, and venipuncture in the after­
noon was associated with lower production.
The median ex vivo production of TNF-o: in all patients 
with FUO was 4.2 ng/mL (range, 0-9,8). Patients with neo­
plasms and NIID {P <  .05) had significantly lower ex vivo 
production of TNF-a than normal subjects. By multiple regres­
sion analysis, males had lower ex vivo production than females.
Median production of IL-6 in all patients with FUO was 
10,9 ng/mL (range, 3-36.3). Patients with no diagnosis, malig­
nancies, infections, and NIID had significantly lower median 
IL-6 levels than normal controls (P <  .05). Multiple regression 
analysis indicated that patients without fever at venipuncture 
had less IL-6 than did patients with fever (P =  .02).
The median ex vivo production of IL-lra of patients with 
FUO was 11.4 ng/mL (range, 0-21.6). There were no signifi­
cant differences among the 6 groups. By multivariate analysis, 
some explanatory variance was found: When the period be­
tween first day of fever and venipuncture was long, ex vivo 
production of IL-lra was higher, and patients whose body tem­
peratures rose after venipuncture had higher levels of IL-lra.
We found positive correlations between some circulating
cytokines: IL-1 (3 and TNF-a (r = .31, P <  .001) and IL-lra 
and IL-6 (r -  .33, P <  .001). Stronger positive correlations 
were found for ex vivo production pf IL-1/3 and TNF-a (r =  
.70, P < .001), IL-1/? and IL-6 (r = .65, P <  .001), and TNF- 
a and IL-6 (/* = .53, P <  .001).
There was negative correlation for all circulating cytokines 
and their ex vivo production, but this was significant only for 
IL-lra (r = -.53, P < .001).
When we compared circulating and ex vivo production of 
cytokines of the 7 patients who died with levels for patients 
still alive, only median circulating IL-lra differed significantly 
for those who died (950 pg/mL; range, 525-1550) and for 
surviving patients (310 pg/mL; range, 20-2100; P <  .001).
In 35 of the 123 patients with longstanding fever, no in­
creased circulating cytokines could be measured (18 of 39 
without a diagnosis and 17 of 84 with diagnoses; P <  .005).
Discussion
We believe this study is the first prospective investigation 
of the role of the putative pyrogenic cytokines in FUO. We 
measured concentrations and ex vivo production of cytokines 
and evaluated their diagnostic value. Taken together, no pyro­
genic cytokines were responsible for the fever in many patients 
and we could not link certain pyrogenic cytokines with disease 
categories. Despite the wide scatter, patients with infections 
had high IL-lia and TNF-a plasma levels, patients with neo­
plasms had high 1L-1/3 and IL-lra plasma levels and low ex
vivo production of TNF-a, and patients with NIID had low 
production of TNF-a.
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Figure  1. Circulating interleukin (IL)-l/?, tumor necrosis factor (TNF)-a:, IL-6 , and IL -lra  (pg/mL) in 123 patients with FUO by diagnosis. 
Symbols indicate subgroups— bacterial infection, hematologic tumors, and vasculitis/mixed cryoglobulinemia (O); nonbacterial infection, solid 
tumors, and granulomatous diseases ( • ) ;  connective tissue (+ ). Bars indicate medians. Nos. are median concentrations (pg/mL). * P  <  .05.
The possibility that cytokine patterns might be useful in the 
diagnostic work-up of a patient with FUO has been suggested. 
Patients with viral meningitis have lower concentrations of 
TNF-a in cerebrospinal fluid than do patients with bacterial 
meningitis [6]. Similarly, patients with granulocytopenia and 
proven bacterial infections have higher IL-6 concentrations 
than patients with FUO [7], Appreciable concentrations of 
IL-1/? and TNF-a have been found in patients with meningo­
coccal disease [8] but not in patients with typhoid fever [9]. 
Variation in cytokine levels has been observed in other dis­
eases, including chronic inflammatory bowel disease [10], 
rheumatoid arthritis [11], and Hodgkin’s disease [12]. In our 
series of patients with FUO, despite significant differences 
in concentrations and ex vivo production capacity of cyto­
kines and inhibitors between subgroups, these measurements 
did not aid in the diagnostic process. Pathophysiologic inter­
pretation of the cytokine patterns found is difficult because 
of the degree of variation between patients with the same 
disease. It may well be that factors such as genetic back­
ground and nutritional status are predominant determinants 
in individual cytokine responses.
IL-1/3, TNF-a, and IL-6 are thought to be the major endoge­
nous pyrogens. Despite long-standing fever in all patients and 
a febrile state in most, we were unable to detect elevated con­
centrations of pyrogenic cytokines in all patients. There are a 
number of possible explanations for this phenomenon. Since 
the pyrogenic cytokines have a short half-life, it is possible 
that even if the set point in the hypothalamus had become 
elevated, the molecules had disappeared by the time of sam­
pling. Alternatively, the set point may be raised by cytokines 
that are produced at the level of the organum vasculosum of 
the lamina terminalis [2]. These cytokines would then be in­
duced by a circulating exogenous pyrogen or some endogenous 
molecule. Finally, there is the possibility that a major pyrogenic 
cytokine has yet to be identified.
Despite reports of increased concentrations of TNF-a: in 
patients with fatal infection [13], TNF-a, IL-1/3, and IL-6 con­
centrations were similar in patients who died of febrile illness
194 Concise Communications JID 1997; 175 (January)
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Figure 2. Ex vivo production of interleukin (IL)-l/?, tumor necrosis factor (TNF)-a, IL-6, and IL-lra (ng/mL) in 123 patients with FUO by 
diagnosis. Symbols indicate subgroups— bacterial infection, hematologic tumors, and vasculitis/mixed cryoglobulinemia (O); nonbacterial 
infection, solid tumors, and granulomatous diseases (ft); connective tissue (+). Bars indicate medians. Nos. are median concentrations (pg/ 
mL), * P <  .05.
and in survivors. However, the median concentration o f the 
antiinflammatory cytokine IL -lra  in those who died was higher 
than in surviving patients, pointing to greater cytokine activa­
tion in the former group.
In conclusion, this prospective study shows subtle changes 
in circulating concentrations and in ex vivo production o f cyto­
kines associated with FUO, but the measurements did not help 
in the diagnostic process o f the intriguing clinical problem of 
FUO.
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Diagnosis of Measles with an IgM Capture EIA: The Optimal Timing of 
Specimen Collection after Rash Onset
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The optimal timing for collection of a single serum specimen to diagnose measles by using a 
monoclonal antibody-capture EIA was evaluated. Results of testing paired serum samples from 
166 measles cases with at least 1 IgM-positive specimen were analyzed. Among persons whose 
second samples were IgM-positive, the seropositivity rate for first samples was 77% when collected 
within 72 h and 100% when collected 4-11 days after rash onset. Among unvaccinated persons 
whose first samples were IgM-positive, the rate for IgM positivity of second specimens declined 
from 100% at 4 days to 94% at 4 weeks after rash onset, then declined further to 63% at 5 weeks, 
Some previously vaccinated persons became IgM-negative during the third week after rash onset. 
In general, a single serum specimen collected between 72 h and 4 weeks after rash onset can be 
used to diagnose most cases of measles with an IgM capture EIA.
Measles continues to be a major health problem worldwide, 
with ~45 million cases globally each year [1]. The Pan Ameri­
can Health Organization is working toward the elimination of 
measles from Central and South America [2]. These elimination 
efforts have created renewed interest in sensitive and specific 
diagnostic assays that can be used by countries throughout the 
world to diagnose measles infections.
Received 12 April 1996; revised 29 July 1996.
Reprints or correspondence: Dr. Rita Helfand, Respiratory and Enteric Vi­
ruses Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd.# 
Mailstop G-17, Atlanta, GA 30333.
T he Jou rna l of Infectious Diseases 1997;175:195-9 
© 1997 by The University o f Chicago. All rights reserved.
0022-1899/97/7501-0032S01.00
Currently, many different serologic techniques are used to 
diagnose measles; these are based on detecting either IgM or 
IgG antibodies [3,4]. Serologic assays that detect TgG antibod­
ies, including hemagglutination inhibition, RIA, plaque reduc­
tion neutralization, and microneutralization, have the disadvan­
tage of requiring acute- and convalescent-phase specimens to 
measure a rise in IgG antibodies. Assays that detect IgM anti­
bodies, such as RIAs and El As, often can be used to diagnose 
measles by testing only a single serum specimen. RIAs are 
reliable but have the disadvantage of requiring adequate facili­
ties to store, use, and dispose of radioactive material. Most 
commercially available EIA kits use an indirect format. Al­
though this format is relatively simple to use, its increased risk 
of false-positive results [5] and lower sensitivity can lead to 
m is classification of individual cases and outbreaks of measles-
